On September 3, 2025, the three-day 2025 CPHI&PMEC Pharmaceutical Industry Exhibition (Shenzhen) came to a successful conclusion at the Shenzhen Convention and Exhibition Center. During the exhibition, the "CPHI&PMEC Pharmaceutical Industry Exhibition: International Drug Production Supervision Policy Hotspot Analysis and Application Practice" jointly organized by the Pharmaceutical Technology Committee of the China Medical Education Association and PMEC was successfully held on the morning of the 3rd, attracting more than 100 industry professionals to participate on site.

The Shenzhen CPHI On-site

Ms. Feng, vice general manager of gempex China and senior GMP expert, had a special report entitled "Holding and Access System and Quality System Management Requirements for the Global Drugs" as one of the keynote speakers. She analyzed the quality management system challenges faced by enterprises in their global layout by focusing on the differences in drug owner (MAH) systems and access mechanisms in the three major markets of China, USA, and EU. Based on multiple practical cases, she provided a series of compliance strategies and implementation suggestions for enterprises. During the speech, the attendees listened attentively and frequently recorded the key points of international regulatory policies mentioned in the speech, showing a strong interest.

The Speech On-site

This forum closely focuses on the actual needs of internationalization and compliance transformation in the pharmaceutical industry, providing participants with highly valuable reference content. As an international GMP consulting and execution agency rooted in Germany for 23 years, gempex, with over 5000 global project experiences, continues to provide pharmaceutical companies with one-stop compliance solutions covering factory quality management, computerized system validation, and international market access, helping Chinese drugs to enter the world with high quality.

Contact Us 

Hot-line: 400-166-2002

E-mail: info-cn@gempex.com